January 15, 2019 5:39pm

The sector is weak yet, there is proof of life – it’s UP <as the shorts cover (?)>

Volume stat:  very low as 1 out of the 11 upside had higher (than the 3 month average) volume and 3 out of the 33 downside experienced greater volume (than the 3 month average) volume

Pre-open Indication: 3 HITs and 1 MISS

Out and about: AxoGen (AXGN +$0.59 to $16.61) RECON® study supporting its Biologic License Application (BLA) submission for Avance® Nerve Graft has reached its current enrollment milestone of 170 subjects. RECON® is AXGN’s P3 pivotal study comparing Avance® Nerve Graft to manufactured conduits.


RMi outlines preludes and aftermaths defining the daily dose of facts, investment thesis and objectivity!

Members only. Please login.